Advertisement

Molekulare Grundlagen des sporadischen Mammakarzinoms

  • Bettina Kuschel
  • Matthias W. Beckmann
Part of the Molekulare Medizin book series (MOLMED)

Zusammenfassung

Neben den klassischen Parametern
  • Staging (TNM),

  • Grading und

  • der histologischen Einordnung eines Tumors

gewinnt die „molekulare Stratifizierung“ von Malignomen aufgrund der Fortschritte der molekularen Zytologie und Genetik zunehmend an Bedeutung. Von diesen neuen Methoden in der Tumorforschung wird erwartet, dass eines Tages Tumoren hinsichtlich ihrer Prognose und ihres Therapieansprechens genauer eingeordnet und neue Angriffspunkte für Therapeutika geschaffen werden können. Die Verbesserung von Früherkennungsmöglichkeiten und eine gezielte Prävention sind weitere Ziele. Allerdings sind die meisten Gene, die an der Initiation und Progression von Tumoren beteiligt sind, nicht identifiziert oder in ihrer komplexen Funktion nicht aufgeklärt, sodass die molekulare Tumorforschung im Hinblick auf die gesteckten Ziele noch in den Kinderschuhen steckt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adeyinka A, Kytola S, Mertens F, Pandis N, Larsson C (2000) Spectral karyotyping and chromosome banding studies of primary breast carcinomas and their lymph node metastases. Int J Mol Med 5:235–240PubMedGoogle Scholar
  2. An HX, Niederacher D, Beckmann MW et al. (1995) ERB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues. Int J Cancer 64:291–297PubMedGoogle Scholar
  3. Anderson SF, Schlegel BP, Nakajima T, Wolpin ES, Parvin JD (1998) BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat Genet 19:254–256PubMedGoogle Scholar
  4. Anzick SL, Kononen J, Walker RL et al. (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965–968PubMedGoogle Scholar
  5. Aprelikova ON, Fang BS, Meissner EG et al. (1999) BRCA1-associated growth arrest is RB-dependent. Proc Natl Acad Sci USA 96:11866–11871PubMedCentralPubMedGoogle Scholar
  6. Archer S, Eliopoulos A, Spandidos D et al. (1995) Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72:1259–1266PubMedCentralPubMedGoogle Scholar
  7. Arrowsmith CH (1999) Structure and function in the p53 family. Cell Death Differ 6:1169–1173PubMedGoogle Scholar
  8. Bailar JC, Gornik H.L. (1997) Cancer undefeated. N Engl J Med 336:1569–1574PubMedGoogle Scholar
  9. Barlow C, Brown KD, Deng CX, Tagle DA, Wynshaw-Boris A (1997) Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways. Nat Genet 17:453–456PubMedGoogle Scholar
  10. Baselga J, Tripathy D, Mendelsohn J et al. (1996) Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monodonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 14:737–744PubMedGoogle Scholar
  11. Baselga J, Scidman AD, Rosen PP, Norton L (1997) HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology 11:43PubMedGoogle Scholar
  12. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized anti-HER2 antibody (herceptin) enhances the antitumor activity of paclitaxel and doxorubiein against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825–2831PubMedGoogle Scholar
  13. Baskaran R, Wood LD, Whitaker LL et al. (1997) Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 387:516–519PubMedGoogle Scholar
  14. Baylin SB, Herman JG, Herman JR, Vertino PM, Issa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72:141–196PubMedGoogle Scholar
  15. Beckmann MW, Mohrmann T, Niederacher D (1997a) Wirkungsmechanismen von Steroidhormonen und Steroidhormon-Antagonisten und ihre Bedeutung für die Tumorkarzinogenese.Gynäkologe 30:617–623Google Scholar
  16. Beckmann MW, Niederacher D, Schnuerch HG, Gusterson BA, Bender HG (1997b) Multistep careinogenesis of breast cancer and tumour homogeneity. J Mol Med 75:429–439PubMedGoogle Scholar
  17. Beckmann MW, Kuschel B, Schmutzler RK (1998) Hereditäre Karzinomsyndrome in der Frauenheilkunde. Gynäkologe31:1039–1045Google Scholar
  18. Beckmann MW, Hanstein B, Niederacher D, Jap D, Kuschel B, Bender HG (2000a) Wirkmechanismen ovarieller Steroidhormone und Antiöstrogene in der Karzinogenese der Mamma und des Endometriums. Geburtshilfe Frauenheilkd 60:71–76Google Scholar
  19. Beckmann MW, Jap D, Kuschel B et al. (2000b) Ovarielle Steroidhormone und Anti-östrogene: Risiken und Prävention in der Karzinogenese der Mamma und des Endometriums in der Postmenopause. Geburtshilfe Frauenheilkd60:77–85Google Scholar
  20. Bernards R (1999) CDK-independent activities of D type cyelins.Biochim Biophys Acta 1424:17–22Google Scholar
  21. Berns E, Klijn J, Putten W van et al. (1998) p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. J Clin Oncol16:121–127PubMedGoogle Scholar
  22. Berx G, Cleton-Jansen AM, Nollet F et al. (1995) E-Cadherin is a tumor/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 14:6107–6115PubMedCentralPubMedGoogle Scholar
  23. Biscardi JS, Tice DA, Parsons SJ (1999) c-Src, receptor tyrosine kinases and human cancer. Adv Cancer Res 76:61–119PubMedGoogle Scholar
  24. Biunno I, Pozzi MR, Pierotti MA, Pilotti S, Cattoretti G, Della Porta G (1988) Structure and expression of oncogenes in surgical specimens of human breast carcinomas. Br J Cancer 57:464–468PubMedCentralPubMedGoogle Scholar
  25. Brzozowski AM, Pike ACW, Dauter Z (1997) Molecular basis of agonism and antagonism in the oestrogen receptor.Nature 389:753–758PubMedGoogle Scholar
  26. Buillons LC, Notterman DA, Chung LS, Levine AJ (1997) Expression of wild-type alpha-catenin protein in cells with a mutant alpha-catenin gene restores both growth regulation and tumor suppressor activities. Mol Cell Biol 17:4501–4508Google Scholar
  27. Carlomagno C, Perrone F, Gallo C et al. (1996) c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14:2702–2708PubMedGoogle Scholar
  28. Chen J, Birkholtz GG, Lindbiom P, Rubio C, Lindbiom A (1998a) The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res 58: 1376–1379PubMedGoogle Scholar
  29. Chen J, Silver DP, Walpita D et al. (1998b) Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 2:317–328PubMedGoogle Scholar
  30. Coleman-Krnacik S, Rosen JM (1994) Differential temporal and spatial gene expression of fibroblast growth factor family members during mouse mammary gland development. Mol Endocrinol 8:218–229PubMedGoogle Scholar
  31. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713–1727Google Scholar
  32. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350:1047–1059Google Scholar
  33. Coutts LC, Murphy AS (1998) Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res 58:4071–4074PubMedGoogle Scholar
  34. Critchlow SE, Jackson SP (1998) DNA end-joining: from yeast to man. Trends Biochem Sci 23:394–398PubMedGoogle Scholar
  35. Cummings SR, Eckert S, Krueger KA et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 281:2189–2192PubMedGoogle Scholar
  36. Dang CV (1999) c-Myc target genes involved in cell growth, apoptosis and metabolism. Mol Cell Biol 19:1–11PubMedCentralPubMedGoogle Scholar
  37. Dati C, Antoniotti S, Taverna D, Perroteau I, De Borloti M (1990) Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 5:1001–1006PubMedGoogle Scholar
  38. DeBortoli M, Dati C, Antoniotti S, Maggiora P, Sapei ML (1992) Hormonal regulation of c-erb-b2 oncogene expression in breast cancer cells. J Steroid Biochem Mol Biol 43:21–25Google Scholar
  39. Deming SL, Nass SJ, Dickson RB, Trock BJ (1999) Amplification in breast cancer: a meta analysis of its frequency and assoeiation with risk factors. Proc Annu Meet AACR Abstract 1358Google Scholar
  40. DePotter CR, Beghin C, Makar AP, Vandekerckhove D, Roels HJ (1990) The neu-oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients. Int J Cancer 45:55–58Google Scholar
  41. Devilee P, Cornelisse CJ (1994) Somatic genetic changes in human breast cancer. Biochim Biophys Acta 1198:113–130PubMedGoogle Scholar
  42. Dickson RB, Lippmann ME (2000) Pathogenesis of breast cancer. In: Harris JR, Lippmann ME, Morrow M, Osborne CK (eds) Diseases of the breast. Lippincott Williams & Wilkins, Philadelphia, p 289Google Scholar
  43. Dillon DA, Howe CL, Bosari S, Costa J (1998) The molecular biology of breast cancer: accelerating clinical applications. Crit Rev Oncogn 9:125–140Google Scholar
  44. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA (1997) High titer HER-2/neu protein specific antibody immunity can be detected in patients with early stage breast cancer. J Clin Oncol 15:3363–3367PubMedGoogle Scholar
  45. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF (1999) A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8:843–854PubMedGoogle Scholar
  46. Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: overview of the randomised trials. Lancet 351:1451–1467Google Scholar
  47. Easton DF (1994) Cancer risks in A-T heterozygotes. Int J Radiat Biol [Suppl 6] 66:S177–S182PubMedGoogle Scholar
  48. Easton DF (1999) How many breast cancer predisposition genes are there? http://breast-cancer-research.com/vol1no1/23aug/editorial/1Google Scholar
  49. Ekstrand AJ, Longo N, Hamid ML et al. (1994) Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9:2313–2320PubMedGoogle Scholar
  50. Elledge RM, Allred DC (1998) Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 52:79–98PubMedGoogle Scholar
  51. Eng (1998) Genetics of Cowden syndrome: through the looking glass of oncology. Int J Oncol 12:701–710PubMedGoogle Scholar
  52. Escot C, Theillet C, Lidereau R et al. (1986) Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci USA 83:4834–4838PubMedCentralPubMedGoogle Scholar
  53. Esteller M, Silva JM, Dominguez G et al. (2000) Promoter hypermethylation and BRCAI inactivation in sporadic breast and ovarian tumors. J Natl Cancer lust 92:564–569Google Scholar
  54. Fan S, Wang J, Yuan R et al. (1999) BRCAI inhibition of estrogen receptor signaling in transfected cells. Science 284: 1354–1356PubMedGoogle Scholar
  55. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767PubMedGoogle Scholar
  56. Fisher B, Costantino JP, Wickerham DL et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer lust 90:1371–1388Google Scholar
  57. FitzGerald MG, Bean JM, Hegde SR et al. (1997) Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 15:307–310PubMedGoogle Scholar
  58. Folkman J, Watson K, Ingber D, Hanahan D (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58–61PubMedGoogle Scholar
  59. Ford D, Easton DF, Stratton M et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCAI and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689PubMedCentralPubMedGoogle Scholar
  60. Freihoff D, Kempe A, Beste B et al. (1999) Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br J Cancer 79:754–758PubMedCentralPubMedGoogle Scholar
  61. Freije JM, MacDonald NJ, Steeg PS (1996) Differential gene expression in tumor metastasis: Nm23. Curr Topic Microbiol Immunol 213:215–232Google Scholar
  62. Fujimoto N, Katzenellenbogen BS (1994) Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen-selectivity and promotor-dependence.Mol Endocrinol 8:296–304PubMedGoogle Scholar
  63. Gatti RA, Boder E, Vinters HV, Sparkes RS, Norman A, Lange K (1991) Ataxia-teleangiectasia: an interdisciplinary approach to pathogenesis. Medicine (Baltimore) 70:99–117Google Scholar
  64. Gayther SA, Warren W, Mazoyer S et al. (1995) Germline mutations of the BRCAI gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 11:428–433PubMedGoogle Scholar
  65. Gayther SA, Mangion J, Russell P et al. (1997) Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 15:103–105PubMedGoogle Scholar
  66. Gee JM, Barroso AF, Ellis IO, Robertson JF, Nicholson RI (2000) Biological and clinical associations of c-jun activation in human breast cancer. Int J Cancer 89:177–186PubMedGoogle Scholar
  67. Gelmann EP (1996) Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog? J Natl Cancer Inst 88:224–226PubMedGoogle Scholar
  68. Gibson S, Tu S, Oyer R, Anderson SM, Johnson GL (1999) Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem 274:17612–17618PubMedGoogle Scholar
  69. Goldhirsch A, Glick JH, Gelber RD, Senn HJ (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90:1601–1608PubMedGoogle Scholar
  70. Gualberto A, Aldape K, Kozakiewicz K, Tlsty TD (1998) An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci USA 95:5166–5171PubMedCentralPubMedGoogle Scholar
  71. Gudas JM, Nguyen H, Li T, Cowan KH (1995) Hormone-dependent regulation of BRCAI in human breast cancer cells. Cancer Res 55:4561–4565PubMedGoogle Scholar
  72. Gullick WJ, Srinivasan R (1998) The type 1 growth receptor family: new ligands and receptors and their role in breast cancer. 52:43–53Google Scholar
  73. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M (1994) Estrogen receptor-associated protein: possible mediators of hormone-induced transcription. Science 264:455–1458Google Scholar
  74. Hankins GR, DeSousa AT, Bentley MR et al. (1996) M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene 12:2003PubMedGoogle Scholar
  75. Hanstein B, Bender HG (1998) Molekularbiologie des östrogenrezeptors und seine Regulation durch östrogene und Antiöstrogene. Gynäkologe 31:1046–1050Google Scholar
  76. Hanstein B, Eckner R, DiRenzo J et al. (1996) p300 is a component of an estrogen receptor coactivator complex. Proc Natl Acad Sci USA 96: 11540–11545Google Scholar
  77. Harari D, Tzahar E, Romano J et al. (1999) Neuregulin-4: av novel growth factor that acts through the ErbB-4 receptor tyrosin kinase. Oncogene 18:2681–2689PubMedGoogle Scholar
  78. Harris CC (1995) The 1995 Walter Hubert Lecture-molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumor-suppressor gene. Br J Cancer 73:261–269Google Scholar
  79. Hattori M, Fujiyama A, Taylor TD et al. (2000) The DNA sequence of human chromosome 21. Nature 405:311–319PubMedGoogle Scholar
  80. Hermeking H, Lengauer C, Polyak K et al. (1997) 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1:3–11PubMedGoogle Scholar
  81. Holmes WE, Sliwkowski MX, Akita RW et al. (1992) Identification of heregulin, a specific activator of p185erbB2. Science 256:1205–1210PubMedGoogle Scholar
  82. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L (1996) Nuclear receptor coactivators and corepressors. Mol Endocrinol 10:1167–1177PubMedGoogle Scholar
  83. Hsu LC, White RL (1998) BRCAI is associated with the centrosome during mitosis. Proc Natl Acad Sci USA 95:12983–12988PubMedCentralPubMedGoogle Scholar
  84. Ignar-Trowbridge DM, Nelson KG, Bidwell MC et al. (1992) Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc Natl Acad Sci USA 89:4658–4562PubMedCentralPubMedGoogle Scholar
  85. Inskip HM, Kinlen LJ, Taylor AM, Woods CG, Arlett CF (1999) Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br J Cancer 79: 1304–1307PubMedCentralPubMedGoogle Scholar
  86. Invargsson S (1999) Molecular genetics of breast cancer progression.Cancer Biol 9:277–288Google Scholar
  87. Jagus R, Joshi B, Barber GN (1999) PKR, apoptosis and cancer. Int J Biochem Cell Biol 31:123–138PubMedGoogle Scholar
  88. Janin N, Andrieu N, Ossian K et al. (1999) Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br J Cancer 80:1042–1045PubMedCentralPubMedGoogle Scholar
  89. Kanonen J, Bubendorf L, Kallioniemi A et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844–847Google Scholar
  90. Kato S, Endoh H, Masuhiro Y et al. (1995) Activation of the estrogen receptor through phosphorylation by mitogenactivated protein kinase. Science 270:1491–1494PubMedGoogle Scholar
  91. Katzenellenbogen BS, Montano MM, Le Goff P et al. (1995) Antiestrogens. Mechanisms and actions in target cells. J Steroid Biochem Mol Biol 53:55–64Google Scholar
  92. Kharbanda S, Pandey P, Jin S et al. (1997) Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature 386:732–735PubMedGoogle Scholar
  93. Kinzier KW, Vogelstein B (1997) Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386:761–763Google Scholar
  94. Klijn JG, Berns PM, Schmitz PI, Foerkens JA (1992) The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13:3–17PubMedGoogle Scholar
  95. Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823PubMedCentralPubMedGoogle Scholar
  96. Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N (1993) An association between the risk of cancer and mutations in the HRASI minisatellite locus. N Engl J Med 329:517–523PubMedGoogle Scholar
  97. Kuschel B, Betz B, Niederacher D, Beckmann MW (2000a) Hereditary breast cancer: molecular and chemical differences to sporadic breast cancer. J Women Cancer 2:93–100Google Scholar
  98. Kuschel B, Lux MP, Bender HG, Beckmann MW (2000b) Prevention and therapy for BRCA1/2 mutation carriers and woman at high risk for breast and ovarian cancer.Eur J Cancer Prev 9:139–150PubMedGoogle Scholar
  99. Laake K, Launonen V, Niederacher D et al. (1999) Loss of heterozygosity at 11q23.1 and survival in breast cancer: results of a large European study. Breast Cancer Somatic Genetics Consortium. Genes Chromosomes Cancer 25:212–221Google Scholar
  100. Lahooti H, White R, Danielian PS, Parker MG (1994) Characterization of ligand-dependent phosphorylation of the estrogen receptor. Mol Endocrinol 8:182–188PubMedGoogle Scholar
  101. Lakhani SR, Jacquemier J, Sloane JP et al. (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCAI and BRCA2 mutations. J Natl Cancer Inst 90: 1138–1145PubMedGoogle Scholar
  102. Lee H, Trainer AH, Friedman LS et al. (1999) Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol Cell 4: 1–10PubMedGoogle Scholar
  103. Lemoine NR, Barnes DM, Hollywood DP et al. (1992) Expression of the ERBB3 gene product in breast cancer. Br J Cancer 66:1116–1121PubMedCentralPubMedGoogle Scholar
  104. Lenferink AE, Pinkas-Kramarski R, Poil ML van den et al. (1998) Differential endocytic routing of homo-and heterodimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 17:3385–3397PubMedCentralPubMedGoogle Scholar
  105. Levi F, Lucchini F, La Vecchia C, Negri E (1999) Trends in mortality from cancer in the European Union, 1955-94. Lancet 354:742–743Google Scholar
  106. Li S, Chen PL, Subramanian T et al. (1999) Binding of CUP to the BRCT repeats of BRCAI involved in the transcription regulation of p21 is disrupted upon DNA damage. J Biol Chem 274:11334–11338PubMedGoogle Scholar
  107. Lu YJ, Morris JS, Edwards PA, Shipley J (2000) Evaluation of 24-color multifluor-fluorescence in-situ hybridization(M-FISH) karyotyping by comparison with reverse chromosome painting of the human breast cancer cell line T-47D. Chromosome Res 8:127–132PubMedGoogle Scholar
  108. Maia DM (1999) Immunohistochemical assays for HER2 overexpression. J Clin Oncol 17:1650PubMedGoogle Scholar
  109. Markopopoulous C, Berker U, Wilson P, Gazet JC, Coombes RC (1988) Estrogen receptor content of normal breast ceUs and breast carcinomas throughout the menstrual cyde. BMJ 296:1349–1351Google Scholar
  110. Medina D, Stephens LC, Bonilla PJ et al. (1998) Radiationinduced tumorigenesis in preneoplastic mouse mammary glands in vivo: significance of p53 status and apoptosis. Mol Carcinog 22:199–207PubMedGoogle Scholar
  111. Menard S, Valagussa P, Pilotti S et al. (1999) HER2 overexpression and response to CMF in lymph node positive breast cancer. Proc ASCO 18:69aGoogle Scholar
  112. Menard S, Tagliabue E, Campiglio M, Pupa SM (2000) Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 182:150–162PubMedGoogle Scholar
  113. Molina R, Ciocca DR, Tandon AK et al. (1992) Expression of Her-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and Western blot techniques. Anticancer Res 12:1965–1971PubMedGoogle Scholar
  114. Moscatello DK, Holgado-Madruga M, Godwin AK et al. (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55:5536–5539PubMedGoogle Scholar
  115. Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ (1998) Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 273:200–206PubMedGoogle Scholar
  116. Müschen M, Warskulat U, Beckmann MW (2000) Defining CD95 as a tumor suppressor gene. J Mol Med 78:312–325PubMedGoogle Scholar
  117. Nass SJ, Dickson RB (1997) Defining a role for c-myc in breast tumorigenesis. Breast Cancer Res Treat 44:1–22PubMedGoogle Scholar
  118. Nelson N (2000) Can HER2 status predict response to cancer therapy? J Natl Cancer Inst 92:366–367PubMedGoogle Scholar
  119. Neuman E, Ladha MH, Lin N et al. (1997) Cydin Dl stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol17:5338–5347PubMedCentralPubMedGoogle Scholar
  120. Nicholson RI, McClelland RA, Gee JMW et al. (1994) Epidermal growth factor receptor expression in breast cancer: association with endocrine therapy. Breast Cancer Res Treat 29:117–125PubMedGoogle Scholar
  121. Niederacher D, Beckmann MW (1998) Bedeutung der LOH Analyse für die Identifizierung von Tumorgenen. Medgen 10:256–258Google Scholar
  122. Nielsen NH, Arnerlov C, Emdin SO, Landberg G (1996) Cydin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 74:874–880PubMedCentralPubMedGoogle Scholar
  123. Norman BH, Shih C, Toth JE et al. (1996) Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. J Med Chem 39: 1106–1111PubMedGoogle Scholar
  124. Normanno N, Ciardiello F, Brandt R, Salomon DS (1994) Epidermal growth factor-related peptides in the pathogenesis of human breast cancer. Breast Cancer Res Treat 29:11–27PubMedGoogle Scholar
  125. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609–1618PubMedGoogle Scholar
  126. Paech K, Webb P, Kuiper GGJM (1997) Differential ligand activation of estrogen receptors ERa and ERß at AP 1 sites. Science 277:1508–1510PubMedGoogle Scholar
  127. Pandis N, Heim S, Bardi G, Limon J, Mandahl N, Mitelman F (1992) Improved technique for short-term culture and cytogenetic analysis of human breast cancer. Genes Chromosomes Cancer 5:14–20PubMedGoogle Scholar
  128. Peacock SL, White E, Daling JR, Voigt LF, Malone KE (1999) Relation between obesity and breast cancer in young women. Am J Epidemiol 149:339–346PubMedGoogle Scholar
  129. Pegram M, Hsu S, Lewis G et al. (1999) Inhibitory effects of combinations of HER2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241–2251PubMedGoogle Scholar
  130. Pinkas-Kramarski R, Soussan L, Waterman H et al. (1996) Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452–2467PubMedCentralPubMedGoogle Scholar
  131. Pinkel D (1994) Visualizing tumour amplification. Nat Genet 8:107–108PubMedGoogle Scholar
  132. Press MF, Cordon-Cardo C, Slamon DJ (1990) Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5:953–962PubMedGoogle Scholar
  133. Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI (1993) The extracellular domain of the erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8:2917–2923PubMedGoogle Scholar
  134. Rajan JV, Wang M, Marquis ST, Chodosh LA (1996) Brca2 is coordinately regulated with Brcal during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci USA 93:13078–13083PubMedCentralPubMedGoogle Scholar
  135. Rajan JV, Marquis ST, Gardner HP, Chodosh LA (1997) Developmental expression of Brca2 colocalizes with Brcal and is associated with proliferation and differentiation in multiple tissues. Dev Biol 184:385–401PubMedGoogle Scholar
  136. Ramsay G (1998) DNA chips: state of the art. Nat Biotechnol 16:40–44PubMedGoogle Scholar
  137. Reif M, LeJeune S, Scott PAE. et al. (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor ß-l, platelet derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963–969Google Scholar
  138. Robertson KD, Jones PA (2000) DNA methylation: past, present and future directions. Careinogenesis 21:461–467Google Scholar
  139. Robinson MJ, Cobb MH (1997) Mitogen-activated kinase pathways. Curr Opin Cell Biol 9:180–186PubMedGoogle Scholar
  140. Roche PC, Ingle JN (1999) Increased HER2 with U.S. food and drug administration-approved antibody. J Clin Oncol 17:434–435PubMedGoogle Scholar
  141. Rojas-Ateneio A, Gonzalez L, Urdaneta K et al. (1999) Cytogenetic findings in ductal carcinoma of the breast. Invest Clin 40:179–189Google Scholar
  142. Ross JS, Fleteher JA (1999) Her-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 112:53–67Google Scholar
  143. Russo J, Ao X, Grill C, Russo IH (1999) Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 53:217–227PubMedGoogle Scholar
  144. Schlessinger J (1993) How receptor tyrosine kinases activate ras. Trends Bioehern Sci 18:273–275Google Scholar
  145. Schondorf T, Andrack A, Niederacher D et al. (1999) H-ras gene amplification or mutation is not common in human primary breast cancer. Oncol Rep 6:1029–1033PubMedGoogle Scholar
  146. Schwirzke M, Schiemann S, Gnirke AU, Weidle U (1999) New genes potentially involved in breast cancer metastasis. Anticancer Res 19: 1801–1814PubMedGoogle Scholar
  147. Scully R, Chen J, Plug A et al. (1997) Association of BRCAI with Rad51 in mitotic and meiotic cells. Cell 88:265–275PubMedGoogle Scholar
  148. Sharan SK, Morimatsu M, Albrecht U et al. (1997) Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386:804–810PubMedGoogle Scholar
  149. Sherr CJ (1996) Cancer cell cydes. Science 274:1672–1677PubMedGoogle Scholar
  150. Sidransky D, Tokino T, Helzsouer K et al. (1992) Inherited p53 gene mutations in breast cancer. Cancer Res 52:2984–2986PubMedGoogle Scholar
  151. Sivaraman V, Wang H, Nuovo G, Malbon C (1997) Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99:1478–1483PubMedCentralPubMedGoogle Scholar
  152. Slamon DJ, Godolphin W, Jones LA et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712PubMedGoogle Scholar
  153. Slamon DJ, Leyland-Jones B, Shank S (1998) Addition of herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:98aGoogle Scholar
  154. Smith-Warner SA, Spiegelman D, Yaun SS et al. (1998) Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 279:535–540PubMedGoogle Scholar
  155. Somasundaram K, Zhang H, Zeng YX et al. (1997) Arrest of the cell cyde by the tumour-suppressor BRCAI requires the CDK-inhibitor p21WAFl/CiPl. Nature 389:187–190PubMedGoogle Scholar
  156. Spruck CH, Won KA, Reed SI (1999) Deregulated cydin E induces chromosome instability. Nature 401:297–300PubMedGoogle Scholar
  157. Strachnan T, Read AP (1996) Humane Molekulargenetik. Spektrum z:553–557Google Scholar
  158. Taverna D, Antoniotti S, Maggiora P, Dati C, De Bortoli M, Hynes NE (1994) erbB-2 expression in estrogen-receptor positive breast-tumor cells is regulated by growth-modulatory reagents. Int J Cancer 56:522–528PubMedGoogle Scholar
  159. Thor AD, Berry DA, Budman DR et al. (1998) erbB-2, p53 and efficacy of adjuvant therapy in lymph positive breast cancer. J Natl Cancer lust 90:1346–1360Google Scholar
  160. Tirkkonen M, Johannsson O, Agnarsson BA et al. (1997)Distinct somatic genetic changes associated with tumor progression in carriers of BRCAI and BRCA2 germ-line mutations. Cancer Res 57:1222–1227PubMedGoogle Scholar
  161. Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP (1998) Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer21:177–184PubMedGoogle Scholar
  162. Toi M, Ishigaki S, Tominaga T (1998) Metalloproteinases and tissue inhibitors of metalloproteinases. Breast Cancer Res Treat 52:113–124PubMedGoogle Scholar
  163. Torchia J, Rose DW, Inostroza J et al. (1997) The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387:677–684PubMedGoogle Scholar
  164. Tzahar E, Yarden Y (1998) The Erb-B2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromalligands. Biochim Biophys Acta 1377:25–37Google Scholar
  165. Van Diest PJ, Michalides RJ, Jannink L et al. (1997) Cydin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 150:705–711PubMedCentralPubMedGoogle Scholar
  166. Varley JM, Evans DG, Birch JM (1997) Li-Fraumeni syndrome-a molecular and clinical review. Br J Cancer 76:1–14PubMedCentralPubMedGoogle Scholar
  167. Vaughn JP, Cirisano FD, Huper G et al. (1996) Cell cyde control of BRCA2. Cancer Res 56:4590–4594PubMedGoogle Scholar
  168. Verhoog LC, Brekelmans CTM, Seynaeve C et al. (1998) Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCAl. Lancet 351:316–321PubMedGoogle Scholar
  169. Visakorpi T, Hyytinen F, Koivisto P et al. (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401–406PubMedGoogle Scholar
  170. Vos CB, Cleton-Jansen AM, Berx G et al. (1997) E-Cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer 76:1131–1133PubMedCentralPubMedGoogle Scholar
  171. Waha A, Sturne C, Kessler A et al. (1998) Expression of the ATM gene is significantly reduced in sporadic breast carcinomas. Int J Cancer 78:306–309PubMedGoogle Scholar
  172. Wang SC, Lin SH, Su LK, Hung MC (1997) Changes in BRCA2 expression during progression of the cell cycle. Biochem Biophys Res Commun 234:247–251PubMedGoogle Scholar
  173. Watson PH, Pon RT, Shiu RPC (1991) Inhibition of c-myc expression by phosphorothioate antisense oligonueleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res 51:3996–4000PubMedGoogle Scholar
  174. Weiss MM, Hermsen MAJA, Meijer GA et al. (1999) Comparative genomic hybridisation. J Clin Pathol 52:243–251Google Scholar
  175. Welcsh PL, Owens KN, King MC (2000) Insights into the functions of BRCA1 and BRCA2. Trends Genet 16:69–74PubMedGoogle Scholar
  176. Wen D, Peles E, Cuppies R et al. (1992) Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 69:559–572PubMedGoogle Scholar
  177. Weston A, Godbold JH (1997) Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect [Suppl 4] 105:919–926PubMedCentralPubMedGoogle Scholar
  178. Wilson CA, Ramos L, Villasenor MR et al. (1999) Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 21:236–240PubMedGoogle Scholar
  179. Woo RA, McLure KG, Lees-Miller SP, Rancourt DE, Lee PW (1998) DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature 394:700–704PubMedGoogle Scholar
  180. Wooster R, Mangion J, Eeles R et al. (1992) A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet 2:132–134PubMedGoogle Scholar
  181. Wu KJ, Grandori C, Amacker M et al. (1999) Direct activation of TERT transcription by c-myc. Nat Genet 21:220–224PubMedGoogle Scholar
  182. Wyshak G, Frisch RE (2000) Breast cancer among former college athletes compared to non-athletes: a 15-year follow-up. Br J Cancer 82:726–730PubMedCentralPubMedGoogle Scholar
  183. Xu X, Weaver Z, Linke SP et al. (1999) Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 3:389–395PubMedGoogle Scholar
  184. Yashima K, Milchgrub S, Gollahon LS, Maitra A et al. (1998) Telomerase enzyme activity and RNA expression during the multistage pathogenesis of breast carcinoma. Clin Cancer Res 4:229–234PubMedGoogle Scholar
  185. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC (1994) c-erb B-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 54:3260–3266PubMedGoogle Scholar
  186. Zhang LS, Chang CJ, Bacus SS, Hung MC (1995) Suppressed transformation and induced differentiation of HER-2 neu overexpressing breast cancer cells by emodin. Cancer Res 55:3890–3896PubMedGoogle Scholar
  187. Zhang M, Maass N, Magit D, Sager R (1997) Transactivation through Ets and Ap 1 transcription sites determines the expression of the tumor-suppressing gene maspin. Cell Growth Differ 8:179–186PubMedGoogle Scholar
  188. Zhang LS, Lau YK, Xia W, Hortobagyi GN, Hunh MC (1999) Tyrosine kinase inhibitor emodin suppresses growth of HER2/neu overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paelitaxel. Clin Cancer Res 5:343–353PubMedGoogle Scholar
  189. Zwijsen RM, Wientjens E, Klompmaker R, Sman J van der, Bernards R, Michalides RJ (1997) CDK-independent activation of estrogen receptor by cyelin Dl. Cell 88:405–415PubMedGoogle Scholar
  190. Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ, Bernards R (1998) Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyelin D 1. Genes Dev 12:3488–3498PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • Bettina Kuschel
  • Matthias W. Beckmann

There are no affiliations available

Personalised recommendations